Netarsudil (Rhokiinsa) or netarsudil + latanoprost (Roclanda) in chronic glaucoma: not acceptable Prescrire IN ENGLISH - Spotlight ''Netarsudil (Rhokiinsa°) or netarsudil + latanoprost (Roclanda°) in chronic glaucoma: not acceptable'', 1 July 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue network Offers * Subscribe or renew my subscription * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Netarsudil (Rhokiinsa°) or netarsudil + latanoprost (Roclanda°) in chronic glaucoma: not acceptable SpotlightEvery month, the subjects in Prescrire’s
Netarsudil / latanoprost (Roclanda) - elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension 1 Published 10 February 2025 1 SMC2720 netarsudil plus latanoprost eye drops solution (Roclanda®) Santen UK Limited 10 January 2025 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission netarsudil plus latanoprost (Roclanda®) is accepted for restricted use within NHSScotland. Indication under review: for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle
GVS advice on latanoprost/netarsudil (Roclanda) for the treatment of glaucoma and ocular hypertension GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension | Report | National Health Care Institute Go to content You are here: Home Publications GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension Search within English part of National Health Care Institute Search GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertensionThe National Health Care Institute has assessed whether latanoprost in combination with netarsudil (Roclanda®) can be included in the Medicine Reimbursement System (GVS). These eye drops can be used to treat certain patients
netarsudil mesylate (Rhokiinsa) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * COVID-19Specific areasCOVID-19
Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension. To study and compare the efficacy and safety profile of Rho-kinase inhibitor (netarsudil 0.02%) and prostaglandin analog (bimatoprost 0.01%) both as monotherapy and in combination. Prospective, randomized, monocentric, open-label clinical trial. Patients ≥20 years of age with primary open-angle glaucoma or ocular hypertension (IOP >21 mmHg) were recruited and randomized to receive either netarsudil 0.02%, netarsudil 0.02% + bimatoprost 0.01%, or bimatoprost 0.01% once daily for a period of 12 weeks. IOP and side effects were documented at 4, 8, and 12 weeks. The mean treated IOP ranged 17.51-18.57 mmHg for netarsudil, 15.80-16.46
Topical netarsudil for the treatment of primary corneal endothelial degeneration in dogs. This study evaluated the tolerability and efficacy of the topical rho-kinase inhibitor netarsudil for canine primary corneal endothelial degeneration (PCED). Twenty-six eyes of 21 client-owned dogs with PCED were enrolled in a prospective, randomized, vehicle control clinical trial and received topical netarsudil 0.02% (Rhopressa®) or vehicle control twice daily (BID) for the first 4 months. Then, all patients received netarsudil for the next 4 or 8 months. Complete ophthalmic examination, ultrasonic pachymetry, Fourier-domain optical coherence tomography, and in vivo confocal microscopy were performed at baseline and 1, 2, 4, 6, 8 and 12 months. Effect of netarsudil on central corneal thickness (CCT
Netarsudil (Rhopressa) - To treat glaucoma or ocular hypertension Rhopressa (netarsudil) Ophthalmic Solution * Skip to main page content * Skip to search * Skip to topics menu * Skip to common linksHHS U.S. Department of Health and Human Services U.S. Food and Drug Administration * Follow FDA * En EspañolSearch FDASubmit search * Popular Content * Home * Food * Drugs * Medical Devices * Radiation-Emitting Products * Vaccines, Blood & Biologics * Animal & Veterinary * Cosmetics * Tobacco Products * Home * Drugs * Drug Approvals and Databases * Drugs@FDARhopressa (netarsudil) Ophthalmic Solution * Share * Tweet * Linkedin * Pin it * More sharing options * Linkedin * Pin it * Email * Print RhopressaCompany: Aerie Pharmaceuticals, Inc.Application No.: 208254Approval
MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort) ophthalmic solution in the treatment
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET). A clinical trial evaluated ocular hypotensive efficacy and safety of netarsudil 0.02% once daily (QD) relative to ripasudil 0.4% twice daily (BID). This was a single -masked, randomized, phase 3, superiority study. Japanese patients were randomized to either the netarsudil 0.02% group or the ripasudil 0.4% group in a 1:1 ratio and treated for 4 weeks. The primary efficacy variable was mean diurnal intraocular pressure (IOP) (average of diurnal time points at 09:00, 11:00, and 16:00) at Week 4. A total of 245 patients were included in the primary analysis. At Week 4
Netarsudil in the management of refractory pediatric glaucoma. We performed a retrospective review of patients with refractory pediatric glaucoma who were started on netarsudil at the Wilmer Eye Institute. We found minimally sustained IOP lowering over a 6-month period in 29 eyes of 23 patients. Our results suggest that although netarsudil is an alternative medication in the management
Netarsudil induced corneal honeycombing in childhood glaucomas. Netarsudil is a hypotensive drug that reduces intraocular pressure (IOP). Although it is used to treat corneal decompensation/edema in normotensive eyes, we observed the occurrence of corneal epithelial edema with corneal honeycombing in children with uncontrolled IOP (primary or secondary glaucoma) on maximal topical medication following netarsudil (0.02%) therapy of >2 weeks. Of 16 eyes of 16 children, 9 (56%) developed corneal honeycombing. They were younger than those without honeycombing (median age, 3.1 vs 9.7 years [P = 0.016]), had higher baseline IOP (35.6 ± 7.4 vs 27.2 ± 5.6 mm Hg [P < 0.001]), and usually had preexisting corneal edema (7/9 eyes vs none [P < 0.001]).
Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy. This phase 2 study evaluated the therapeutic potential of netarsudil to reduce corneal edema and to improve vision in patients with Fuchs corneal dystrophy (FCD). Patients ( = 40) with baseline central corneal thickness (CCT) of ≥600 μm and best-corrected visual acuity (BCVA) of 70-20 letters (20/40-20/400 Snellen equivalent) were randomized 1:1 to receive netarsudil once a day (QD) or twice a day (BID) for 8 weeks. Primary endpoint was mean CCT change from baseline at week 4. Netarsudil QD and BID significantly reduced CCT at week 4 [mean change (standard error of mean), 28.4 (7.99) μm, = 0.0021; and 20.1 (8.75) μm, = 0.0335
Axonal Protection by Netarsudil, a ROCK Inhibitor, Is Linked to an AMPK-Autophagy Pathway in TNF-Induced Optic Nerve Degeneration. Netarsudil, a Rho kinase inhibitor with norepinephrine transport inhibitory effect, lowers intraocular pressure, however, its effect on axon damage remains to be elucidated. The aim of the current study was to investigate the effect of netarsudil on TNF-induced axon loss and to examine whether it affects phosphorylated-AMP-activated kinase (p-AMPK) and autophagy in the optic nerve. Intravitreal administration of TNF or TNF with netarsudil was carried out on rats and quantification of axon number was determined. Electron microscopy determined autophagosome numbers. Localization of p-AMPK expression was examined by immunohistochemistry. The changes in p62, LC3-II
Punctal Stenosis Associated with Topical Netarsudil Use. To report a series of patients who developed punctal stenosis secondary to the use of topical netarsudil 0.02% for treatment of glaucoma. Case series. Patients using topical netarsudil for management of glaucoma and noted to have punctal stenosis ipsilateral to the eye(s) being treated with netarsudil were included. Each enrolled patient's chart was reviewed, and alternative causes of punctal stenosis were sought. Photographs were obtained to document punctal stenosis for some patients. Presence of punctal stenosis after topical netarsudil use and resolution of punctal stenosis after cessation of therapy. Sixteen patients had punctal stenosis; 13 developed unilateral punctal stenosis while using netarsudil unilaterally, and 3 patients
Partial Stenosis and Complete Punctal Closure Following Topical Netarsudil Use for Glaucoma. To describe patients who developed partial or complete punctal closure after the use of topical netarsudil in the treatment of glaucoma, with documented reversal of symptoms on drug cessation. This is a retrospective, single-center case series including patients treated with topical netarsudil who were developed punctal disease on the non-netarsudil side. The time from initiation of netarsudil to the documentation of punctal disease ranged from 5-32.2 months (18.41±9.94). In the patients with complete punctal closure, discontinuation of the topical medication led to clinical reappearance of the punctal opening, ranging from 31-83 days after drug cessation (45.75±21.57). In 8 cases, discontinuation
Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma. The purpose of this study was to describe anterior subcapsular cataract development in patients on long-term topical netarsudil use. This clinical observational study summarizes a similar cataract pattern demonstrated in a series of patients from a single physician practice and a university-based outpatient clinic during their routine clinical follow-up visits from October 2020 to August 2021. All patients have been using topical netarsudil once daily for at least 15 months. No anterior capsular changes have been observed in any patient at the time when netarsudil was initiated. Five eyes from 4 patients between the ages of 41 and 61 and 1 eye from a patient aged 84 were found to develop anterior
Topical netarsudil 0.02% as adjunctive therapy in refractory pediatric glaucoma. To evaluate the efficacy of topical netarsudil 0.02% as adjunctive therapy in children with refractory pediatric glaucoma. The medical records of patients ≤18 years diagnosed with pediatric glaucoma or ocular hypertension treated with topical netarsudil 0.02% from June 2019 to March 2022 were reviewed retrospectively. Data collected included age, sex, ethnicity, etiology of glaucoma, history of previous or subsequent glaucoma surgery, and intraocular pressure (IOP) before and after the addition of topical netarsudil. A total of 21 eyes of 16 patients (11 males) were included. Five patients used topical netarsudil in both eyes. Eight patients were Hispanic. The mean number of glaucoma surgeries
Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension - NIHR * About * Our Team * Our Stakeholders * Horizon Scanning * Pipeline Analysis * Imagine Series * Data Science & AI * Get Involved * Devices, Diagnostics & Digital * Research * Insights (Public/Patient) * Insights * Latest Dashboards * Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Interventions: Roclatan (Roclanda; PG324) (fixed dose combination: Netarsudil mesylate; Latanoprost) Indications: Glaucoma, Ocular hypertension Therapeutic Areas: Ophthalmology Year: 2017 Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high